IP Library Granted Patent US 8,415,354
Granted Patent B2
US 8,415,354 · App. 12/390,329 · Granted Apr 9, 2013

Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Inventors: R. Scott Bitner (Pleasant Prairie, WI); Kaitlin E. Browman (Deerfield, IL); Michael E. Brune (Mundelein, IL); Steven Fung (Mount Prospect, IL); Peer B. Jacobson (Libertyville, IL); Lynne E. Rueter (Round Lake Beach, IL); Marina I. Strakhova (Vernon Hills, IL); Jiahong Wang (Lake Bluff, IL); James T. Link (Standford, CA); Yixian Chen (Glenview, IL); Hwan-soo Jae (Glencoe, IL); Jyoti R. Patel (Libertyville, IL); Marina A. Pliushchev (Vernon Hills, IL); Jeffrey J. Rohde (Evanston, IL); Qi Shuai (Dekalb, IL); Bryan K. Sorensen (Antioch, IL); Martin Winn (Deerfield, IL); Dariusz Wodka (Monmouth Junction, NJ); Hong Yong (Libertyville, IL)
Assignee: Abbott Laboratories
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,415,354
App. No.
12/390,329
Granted
Apr 9, 2013
Kind
B2
Abstract

The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Claims (26)

1. A compound of formula (I)

or a therapeutically acceptable salt thereof, wherein

A 1 is cyano or cyanoalkyl;

A 2 , A 3 , and A 4 are each independently hydrogen, alkyl, alkyl-NH-alkyl, alkylcarbonyl, alkylsulfonyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, aryl, arylalkyl, aryloxyalkyl, carboxyalkyl, carboxycycloalkyl, halogen, haloalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, [C(R 8 R 9 )] n —C (O)—R 10 , —O—[C(R 11 R 12 )] p —C(O)—R 13 , —OR 14 , —N(R 15 R 16 ), —CO 2 R 17 , —C(O)—N (R 18 R 19 ), —C(R 20 R 21 )—OR 22 , or —C(R 23 R 24 )—N(R 25 R 26 );

n is 0 or 1;

p is 0 or 1;

R 1 and R 2 are each independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, alkyl-NH-alkyl, aryloxyalkyl, aryl-NH-alkyl, carboxyalkyl, carboxycycloalkyl, heterocycleoxyalkyl, heterocycle-NH-alkyl, cycloalkyl, aryl, arylalkyl, haloalkyl, heterocycle, heterocyclealkyl, heterocycle-heterocycle, and aryl-heterocycle, or R 1 and R 2 together with the atom to which they are attached form a heterocycle;

R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, aryl, and heterocycle, or R 3 and R 4 together with the atom to which they are attached form a ring selected from the group consisting of cycloalkyl and non-aromatic heterocycle;

or R 2 and R 3 together with the atoms to which they are attached form a non-aromatic heterocycle;

R 5 is selected from the group consisting of hydrogen, alkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, aryl, arylalkyl, aryloxyalkyl, heterocycle, heterocyclealkyl, and heterocycleoxyalkyl;

R 6 is selected from the group consisting of hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heterocycle, heterocyclealkyl, and heterocycleoxyalkyl;

R 7 is selected from the group consisting of hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, aryloxy, hydroxy, alkoxy, cycloalkyloxy, heterocycleoxy, heterocycle, heterocyclealkyl, and heterocycleoxyalkyl;

R 8 and R 9 are each independently selected from the group consisting of hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heterocycle, heterocyclealkyl, and heterocycleoxyalkyl, or R 8 and R 9 together with the atom to which they are attached form a ring selected from the group consisting of cycloalkyl and non-aromatic heterocycle;

R 10 is selected from the group consisting of hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, aryloxy, arylalkyl, aryloxyalkyl, hydroxy, alkoxy, cycloalkyloxy, heterocycleoxy, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, and —N(R 27 R 28 );

R 11 and R 12 are each independently selected from the group consisting of hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heterocycle, heterocyclealkyl, and heterocycleoxyalkyl, or R 11 and R 12 together with the atom to which they are attached form a ring selected from the group consisting of cycloalkyl and non-aromatic heterocycle;

R 13 is selected from the group consisting of hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, hydroxy, alkoxy, cycloalkyloxy, heterocycleoxy, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, and —N(R 29 R 30 );

R 14 is selected from the group consisting of hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, haloalkyl, heterocycle, heterocyclealkyl, and heterocycleoxyalkyl;

R 15 and R 16 are each independently selected from the group consisting of hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heterocyclesulfonyl, or R 15 and R 16 together with the atom to which they are attached form a heterocycle;

R 17 is selected from the group consisting of hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heterocycle, heterocyclealkyl, and heterocycleoxyalkyl;

R 18 and R 19 are each independently selected from the group consisting of hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkyloxy, carboxycycloalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, hydroxy, alkoxy, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heterocyclesulfonyl, or R 18 and R 19 together with the atom to which they are attached form a non-aromatic heterocycle;

R 20 , R 21 and R 22 are each independently selected from the group consisting of hydrogen, alkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, aryl, and heterocycle;

R 23 and R 24 are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, carboxyalkyl, carboxycycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, cycloalkyl, aryl, and heterocycle;

R 25 and R 26 are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, carboxyalkyl, carboxycycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, hydroxy, alkoxy, cycloalkyloxy, aryloxy, heterocycleoxy, cycloalkyl, aryl, and heterocycle, or R 25 and R 26 together with the atom to which they are attached form a heterocycle;

R 27 and R 28 are each independently selected from the group consisting of hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkyloxy, carboxycycloalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, hydroxy, alkoxy, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heterocyclesulfonyl, or R 27 and R 28 together with the atom to which they are attached form a non-aromatic heterocycle; and

R 29 and R 30 are each independently selected from the group consisting of hydrogen, alkyl, carboxy, carboxyalkyl, cycloalkyl, cycloalkyloxy, carboxycycloalkyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, hydroxy, alkoxy, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heterocyclesulfonyl, or R 29 and R 30 together with the atom to which they are attached form a non-aromatic heterocycle.

2. The compound of formula (I) as in claim 1 , selected from the group consisting of N—[(E)-5-cyano-2-adamantyl]-2-methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide, and N-[(E)-5-(cyanomethyl)-2-adamantyl]-2-methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}propanamide; or a therapeutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030182/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2009
From: BITNER, R. SCOTT; BROWMAN, KAITLIN E.; BRUNE, MICHAEL E.; FUNG, STEVEN; JACOBSON, PEER B.; RUETER, LYNNE E.; STRAKHOVA, MARINA I.; WANG, JIAHONG; LINK, JAMES T.; CHEN, YIXIAN; JAE, HWAN-SOO; PATEL, JYOTI R.; PLIUSHCHEV, MARINA A.; ROHDE, JEFFREY J.; SHUAI, QI; SORENSEN, BRYAN K.; WINN, MARTIN; WODKA, DARIUSZ; YONG, HONG
To: ABBOTT LABORATORIES
Reel/Frame 022393/0078 →
Continuity (6)
Continuation In Part 11119022 · Apr 29, 2005
Continuation In Part 12195937 · Aug 21, 2008
Provisional Application 60618857 · Oct 13, 2004
Provisional Application 60566265 · Apr 29, 2004
Provisional Application 60957082 · Aug 21, 2007
Related Publication 20090192141A1 · Jul 30, 2009